1. Home
  2. JAZZ vs CHH Comparison

JAZZ vs CHH Comparison

Compare JAZZ & CHH Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • JAZZ
  • CHH
  • Stock Information
  • Founded
  • JAZZ 2003
  • CHH 1939
  • Country
  • JAZZ Ireland
  • CHH United States
  • Employees
  • JAZZ N/A
  • CHH N/A
  • Industry
  • JAZZ Biotechnology: Pharmaceutical Preparations
  • CHH Hotels/Resorts
  • Sector
  • JAZZ Health Care
  • CHH Consumer Discretionary
  • Exchange
  • JAZZ Nasdaq
  • CHH Nasdaq
  • Market Cap
  • JAZZ 6.5B
  • CHH 6.8B
  • IPO Year
  • JAZZ 2007
  • CHH 1997
  • Fundamental
  • Price
  • JAZZ $122.49
  • CHH $145.23
  • Analyst Decision
  • JAZZ Buy
  • CHH Sell
  • Analyst Count
  • JAZZ 14
  • CHH 12
  • Target Price
  • JAZZ $173.93
  • CHH $132.92
  • AVG Volume (30 Days)
  • JAZZ 539.6K
  • CHH 235.3K
  • Earning Date
  • JAZZ 11-06-2024
  • CHH 11-04-2024
  • Dividend Yield
  • JAZZ N/A
  • CHH 0.79%
  • EPS Growth
  • JAZZ 458.10
  • CHH N/A
  • EPS
  • JAZZ 7.04
  • CHH 5.17
  • Revenue
  • JAZZ $3,992,712,000.00
  • CHH $779,010,000.00
  • Revenue This Year
  • JAZZ $7.51
  • CHH $108.95
  • Revenue Next Year
  • JAZZ $6.82
  • CHH $3.15
  • P/E Ratio
  • JAZZ $17.38
  • CHH $28.08
  • Revenue Growth
  • JAZZ 5.23
  • CHH 3.06
  • 52 Week Low
  • JAZZ $99.06
  • CHH $108.91
  • 52 Week High
  • JAZZ $134.17
  • CHH $153.81
  • Technical
  • Relative Strength Index (RSI)
  • JAZZ 53.16
  • CHH 48.14
  • Support Level
  • JAZZ $121.22
  • CHH $143.67
  • Resistance Level
  • JAZZ $126.23
  • CHH $148.30
  • Average True Range (ATR)
  • JAZZ 2.83
  • CHH 3.00
  • MACD
  • JAZZ -0.23
  • CHH -0.89
  • Stochastic Oscillator
  • JAZZ 50.43
  • CHH 28.05

About JAZZ Jazz Pharmaceuticals plc (Ireland)

Jazz Pharmaceuticals is an Ireland-domiciled biopharmaceutical firm focused primarily on treatments for sleeping disorders and oncology. Jazz has nine approved drugs across neuroscience and oncology indications; its portfolio includes Xyrem and Xywav for narcolepsy, Zepzelca for the treatment of metastatic small cell lung cancer, Rylaze for acute lymphoblastic leukemia, and Vyxeos for acute myeloid leukemia. In May 2021, Jazz acquired GW Pharmaceuticals and gained its leading product, Epidiolex for the treatment of severe, rare forms of epilepsy.

About CHH Choice Hotels International Inc.

As of Dec. 31, 2023, Choice Hotels operated 633,000 rooms across 15 brands addressing the economy and midscale segments. Comfort Inn and Comfort Suites are the largest brands (27% of the company's total domestic rooms), while Ascend and Cambria (7% of total domestic rooms) are newer lifestyle and select-service brands. Choice closed on its Radisson acquisition in August 2022, which added around 70,000 rooms. Franchises account for 100% of total revenue, and the United States represent 79% of total rooms in 2023.

Share on Social Networks: